PEI Business Summary

PharmaEngine, Inc. (ticker 4162.TWO), often referred to by its initials PEI, operates as a specialized biopharmaceutical company utilizing a "Virtual Pharmaceutical Company" or "No Research, Development Only" (NRDO) business model. The company generates revenue through a combination of milestone payments, royalties from global licensing agreements, and direct product sales in the Taiwan market. Its primary business segments are focused on the development and commercialization of oncology therapeutics, most notably its flagship product ONIVYDE (irinotecan liposome injection), which is approved globally for metastatic pancreatic cancer. As of March 2026, the company is actively expanding its pipeline with candidates like PEP07 (a CHK1 inhibitor) and PEP08 (a PRMT5 inhibitor) in Phase 1 clinical trials. In the competitive landscape, PharmaEngine maintains a strategic niche between global giants like Jazz Pharmaceuticals and domestic Taiwanese peers such as OBI Pharma, Senhwa Biosciences, and PharmaEssentia, positioning itself as a high-efficiency integrator that leverages international CRO/CDMO partnerships to minimize capital expenditure while maximizing clinical success. Founded in 2003 by Grace Yeh, the company is currently led by President and CEO Dr. Hong-Ren Wang, an MIT-educated materials scientist with extensive drug development experience at Vertex Pharmaceuticals and Johnson & Johnson. The executive team includes ChiHsing Chang as Vice President of Corporate Development and Peggy Tsao as Director of Finance and Accounting, while Brian Shen serves as Senior Director of Clinical and Regulatory Affairs. The company’s governance is supported by a high-profile Board of Directors featuring former Taiwan Minister of Health and Welfare Wen-Ta Chiu and former Taiwan Stock Exchange Chairman Jan-Yau Hsu. Notable institutional backing remains strong, with TTY Biopharm Co., Ltd. and the National Development Fund of the Executive Yuan serving as key strategic investors and board representatives, ensuring deep integration with Taiwan’s national biotechnology infrastructure.